Enzalutamide

Overview

Enzalutamide is an androgen receptor inhibitor used primarily in the treatment of metastatic castration-resistant prostate cancer. It works by blocking the action of male hormones that fuel the growth of cancer cells in the prostate.

API suppliers (4)

Suppliers of Enzalutamide backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• TAPI NL BV1 active DMF
• SHILPA PHARMA LIFESCIENCES LTD1 active DMF
• Laurus Labs LimitedIndia1 active DMF
• MYLAN LABORATORIES LTD

Patent & exclusivity (US)

Per the FDA Orange Book (5 approved US products), the latest listed US patent on Enzalutamide expires 23 Feb 2037 and exclusivity 17 Nov 2026. Generic API sourcing typically opens up once these lapse.

Therapeutic areas